Marseille

Air Liquide and Iveco Group reaffirm their commitment to hydrogen at the inauguration of the first high-pressure hydrogen station for long-haul trucks in Europe

Retrieved on: 
星期二, 六月 27, 2023
Hydrogen, Pressure, Energy policy of the European Union, PIA, Partnership, MI, IVECO, Fos-sur-Mer, Research, Marseille, IVG, Air Liquide, Memorandum of understanding, Ecosystem, Memorandum, Tony Hyams, Iveco, GATE, Natural gas, Renewable energy

This inauguration marks a step forward in the two companies’ commitment to the development of hydrogen mobility in Europe, in line with the Memorandum of Understanding (MoU) signed in December 2021.

Key Points: 
  • This inauguration marks a step forward in the two companies’ commitment to the development of hydrogen mobility in Europe, in line with the Memorandum of Understanding (MoU) signed in December 2021.
  • The new station is also part of H2Haul, the European project co-financed by the Clean Hydrogen Partnership.
  • Air Liquide and IVECO were among the first partners of the H2Haul project when it was launched in 2019.
  • This public-private partnership is supported by the European Union's Horizon 2020 research and innovation programme, Hydrogen Europe and Hydrogen Europe Research.

SICPA AND THE BATAILLON DE MARINS-POMPIERS DE MARSEILLE ARE TESTING AN INNOVATIVE SOLUTION FOR DETECTING PATHOGENS IN AIRCRAFT WASTEWATER

Retrieved on: 
星期五, 五月 6, 2022
COVID-19, Trust, Airport, Population, Solution, Health, SICPA, Marseille, Kratos Defense & Security Solutions, WHO, Partnership, Epidemic, Severe acute respiratory syndrome coronavirus 2, Pandemic, Aircraft, BMPM, COVID-19 testing, Risk, Acquisition, Vaccine, Pharmaceutical industry

LAUSANNE, Switzerland, May 6, 2022 /PRNewswire/ -- The Swiss company SICPA, a world leader in identification, traceability and authentication technologies, and the bataillon de marins-pompiers de Marseille (BMPM – Marseille marine fire brigade), a French innovative biodefense unit, have developed a state-of-the-art technological solution, based on the analysis of aircraft wastewater to help authorities manage the risk of importing pathogens into their territory. The epidemiological data collected gives them a precise view of epidemic dynamics.

Key Points: 
  • It allows the detection of pathogens among a group of passengers entering a given territory in near real time, without the need to know their identity.
  • Governments and health authorities now have a particularly effective tool to prevent and anticipate such health risks.
  • Testing aircraft wastewater has the advantage of being collective, non-invasive and confidential.
  • Its continued existence will enable the early detection of an ever-wider range of pathogens in the future.

SICPA AND THE BATAILLON DE MARINS-POMPIERS DE MARSEILLE ARE TESTING AN INNOVATIVE SOLUTION FOR DETECTING PATHOGENS IN AIRCRAFT WASTEWATER

Retrieved on: 
星期五, 五月 6, 2022
COVID-19, Trust, Airport, Population, Solution, Health, SICPA, Marseille, Kratos Defense & Security Solutions, WHO, Partnership, Epidemic, Severe acute respiratory syndrome coronavirus 2, Pandemic, Aircraft, BMPM, COVID-19 testing, Risk, Acquisition, Vaccine, Pharmaceutical industry

LAUSANNE, Switzerland, May 6, 2022 /PRNewswire/ -- The Swiss company SICPA, a world leader in identification, traceability and authentication technologies, and the bataillon de marins-pompiers de Marseille (BMPM – Marseille marine fire brigade), a French innovative biodefense unit, have developed a state-of-the-art technological solution, based on the analysis of aircraft wastewater to help authorities manage the risk of importing pathogens into their territory. The epidemiological data collected gives them a precise view of epidemic dynamics.

Key Points: 
  • It allows the detection of pathogens among a group of passengers entering a given territory in near real time, without the need to know their identity.
  • Governments and health authorities now have a particularly effective tool to prevent and anticipate such health risks.
  • Testing aircraft wastewater has the advantage of being collective, non-invasive and confidential.
  • Its continued existence will enable the early detection of an ever-wider range of pathogens in the future.

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021

Retrieved on: 
星期五, 十一月 12, 2021
Olive, SITC, Bladder cancer, Prostate, Mab, Therapy, Group B, Breast, MD, Clinical trial, Ovary, Melanoma, Follicular lymphoma, Part, Doctor of Philosophy, Acute leukemia, Teaching hospital, Acute myeloid leukemia, CNRS, Society, Pembrolizumab, Group C, NK, Interferon gamma, Tumor necrosis factor, Research, Cause célèbre, AACR, Society for Immunotherapy of Cancer, Neoplasm, Annual general meeting, Malignancy, Hematological Cancer Research Investment and Education Act, Large-cell lung carcinoma, Antibody, Degenerative disease, Immunology, Infection, INSERM, Immunotherapy, Lung, Pancreatic cancer, Head, T, Vaccine, Pharmaceutical industry, Medical imaging

ImCheck is presenting these updates in addition to two posters covering ICT01 at SITC.

Key Points: 
  • ImCheck is presenting these updates in addition to two posters covering ICT01 at SITC.
  • The conference is taking place in Washington, D.C. and virtually, from November 10 - 14, 2021.
  • All posters presented in the poster hall will be made available as virtual ePosters throughout the SITC 36th Annual Meeting.
  • ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine

Retrieved on: 
星期三, 十月 20, 2021
Olive, Lung, Pancreatic cancer, Head, Group C, Cancer, Melanoma, Research, Interferon gamma, Tumor necrosis factor, Prostate, Neoplasm, T, CD8, BTN, Infection, Patient, Science Translational Medicine, IC, Part, Large-cell lung carcinoma, Breast, Antibody, INSERM, Aix-Marseille University, Oncology, Hematological Cancer Research Investment and Education Act, Leadership, Degenerative disease, Malignancy, Doctor of Pharmacy, CD3, Clinical trial, Immunology, NK, Acute myeloid leukemia, Butyrophilin, Follicular lymphoma, Therapy, CNRS, Group B, Acute leukemia, SITC, Pembrolizumab, AACR, Immunomodulation, Ovary, Vaccine, Management

The publication in the medical journal Science Translational Medicine details ImChecks butyrophilin (BTN)-based immuno-oncology approach and positions ImCheck as a pioneer in a nascent field of immunomodulation.

Key Points: 
  • The publication in the medical journal Science Translational Medicine details ImChecks butyrophilin (BTN)-based immuno-oncology approach and positions ImCheck as a pioneer in a nascent field of immunomodulation.
  • In the first-in-human EVICTION Phase I/IIa clinical trial, ICT01 demonstrated selective activation of V9V2 T cells, causing them to rapidly migrate out of the circulation and into tumor tissue.
  • Furthermore, ICT01-activated V9V2 T cells secrete IFN and TNFa that expands the anti-tumor immune response by recruiting CD3 and CD8 T cells into tumors.
  • BTN3A is essential for the activation of the anti-tumor immune response of V9V2 T cells.

ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021

Retrieved on: 
星期五, 十月 1, 2021
Olive, Therapy, Clinical trial, Cancer, Breast, Neoplasm, SITC, BTN, Hematological Cancer Research Investment and Education Act, Â, Follicular lymphoma, Pancreatic cancer, Melanoma, Tumor necrosis factor, Infection, Degenerative disease, Group B, T, Poster, Annual general meeting, AACR, Society for Immunotherapy of Cancer, Part, Malignancy, Head, Ovary, Immunology, CNRS, Antibody, Immunotherapy, NK, Large-cell lung carcinoma, Prostate, Group C, Mab, Acute leukemia, Acute myeloid leukemia, Interferon gamma, Research, Pembrolizumab, Doctor of Philosophy, INSERM, Lung, Pharmaceutical industry, Medical imaging, Vaccine

It is exciting to have the opportunity to present additional clinical data on ICT01 monotherapy and in combination with pembrolizumab from Part 1 of the ongoing EVICTION trial at SITC 2021.

Key Points: 
  • It is exciting to have the opportunity to present additional clinical data on ICT01 monotherapy and in combination with pembrolizumab from Part 1 of the ongoing EVICTION trial at SITC 2021.
  • BTN3A is essential for the activation of the anti-tumor immune response of 92 T cells.
  • ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
  • In addition, preclinical experiments with ImChecks antagonist antibodies have shown their potential as treatments for a wide range of autoimmune diseases.

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Retrieved on: 
星期四, 九月 23, 2021
Review, Risk, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, AMF, Company, COVID-19, Research, Safety, SEC, Pharmaceutical industry

Disclaimer on forward-looking information and risk factors:

Key Points: 
  • Disclaimer on forward-looking information and risk factors:
    This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including believe, potential, expect and will and similar expressions, is intended to identify forward-looking statements.
  • Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.
  • These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companys commercialization efforts, the Companys continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Companys business, financial condition and results of operations.
  • This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

Retrieved on: 
星期五, 九月 17, 2021
Squamous cell carcinoma, Cancer, Bristol Myers Squibb, European Society for Medical Oncology, Oleclumab, Immune system, Novo Nordisk, Antibody, Durvalumab, Cell biology, Sanofi, Patient, ESMO, IPHA, Natural killer T cell, Oncology, Safety, ORR, IIIC, CRT, IPH, Progression-free survival, Neoplasm, Tumor microenvironment, NSCLC, Lymphatic system, Lung cancer, GLOBE, Intrinsic and extrinsic properties, AstraZeneca, Euronext Paris, PFS, Congress, Vaccine, Pharmaceutical industry

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.

Key Points: 
  • MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.
  • To read more about the Phase 2 COAST results, please see AstraZenecas press release here .
  • Were pleased to see the monalizumab COAST results, particularly the improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer, said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.
  • The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

Retrieved on: 
星期五, 九月 17, 2021
Olive, Acute leukemia, Immune system, Follicular lymphoma, Malignancy, Head, Neoplasm, Breast, Ovary, Large-cell lung carcinoma, CD8, Interferon gamma, Tumor necrosis factor, Research, AACR, Bladder cancer, Prostate, Group B, Lead, Antibody, Hematological Cancer Research Investment and Education Act, The Independent, Acute myeloid leukemia, Immunology, Cancer, Therapy, T, ESMO, Group C, Gustave Roussy, Pancreatic cancer, Part, Melanoma, INSERM, Doctor of Philosophy, Pembrolizumab, Cancer immunotherapy, Clinical trial, NK, Degenerative disease, Infection, Lung, CNRS, Vaccine, Pharmaceutical industry

Patients in this study are heavily pre-treated, including prior checkpoint inhibitor therapy, and at the stage they join the EVICTION trial have no available standard-of-care treatment options.

Key Points: 
  • Patients in this study are heavily pre-treated, including prior checkpoint inhibitor therapy, and at the stage they join the EVICTION trial have no available standard-of-care treatment options.
  • These preliminary signs of disease control are encouraging and, therefore, we are looking forward to additional data readouts from the EVICTION trial.
  • We remain on target to present additional EVICTION trial data later this year.
  • The ongoing EVICTION trial is evaluating ICT01 in patients with advanced relapsed/refractory solid and hematologic cancers who have no remaining standard of care treatment options.

Innate Pharma Reports First Half 2021 Financial Results and Business Update

Retrieved on: 
星期三, 九月 15, 2021
Program, Federal Executive Boards, Income, Investment, Intangibles, IAS, Insurance, Marketing, BLA, Company, Nasdaq, EMA, Depreciation, Risk factor, Risk, IFRS, Biologics license application, COVID-19, Review, Supervisory board, AMF, Board of directors, Mission statement, Accounting, Intrinsic and extrinsic properties, Acquisition, AstraZeneca, European Medicines Agency, Pharmaceutical industry, Cryptocurrency, Health insurance, Asset management, Audit

The companies are currently in a transition period, in which Innate will remain the Biologics License Application (BLA) holder in the U.S until September 30, 2021.

Key Points: 
  • The companies are currently in a transition period, in which Innate will remain the Biologics License Application (BLA) holder in the U.S until September 30, 2021.
  • AstraZeneca will reimburse Innate for all Lumoxiti related costs and expenses, and Innate will remit proceeds from net sales to AstraZeneca.
  • The Company has not made any investments in tangible, intangible or significant financial assets during the first half of 2021.
  • An update of that risk is presented in note G) of the half-year management review as of June 30, 2021.